Roger Sur, MD
Urology · San Diego, CANPI 1932208022
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 74.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $140,406 and has fallen 88.1% since, to $16,669 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $1096.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$264K
- KARL Storz Endoscopy-america$27K
- Cook Incorporated$22K
- Travere Therapeutics, Inc.$11K
- Lumenis, Inc$8K
- Calyxo, Inc.$7K
- plus $17K from 21 others
Across 3 payments — averaging $83,262 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$250K
Across 1 payment — averaging $135,300 each. An ownership or investment interest held by the physician or an immediate family member.
- Calyxo, Inc.$135K
What the payments were for
- Consulting fees$115,75132%
- Speaking & faculty fees$203,50257%
- Travel & lodging$26,0097%
- Food & beverage$10,9283%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 173 | $263,915 |
| KARL Storz Endoscopy-america | 24 | $27,327 |
| Cook Incorporated | 6 | $21,686 |
| Travere Therapeutics, Inc. | 31 | $10,916 |
| Lumenis, Inc | 3 | $8,419 |
| Calyxo, Inc. | 13 | $7,072 |
| Johnson & Johnson(2 entities) | 17 | $5,570 |
| Ethicon Endo-surgery Inc. | 3 | $4,604 |
| Auris Health, Inc. | 2 | $4,000 |
| Cook Medical LLC | 18 | $1,291 |
| Procept Biorobotics Corporation | 8 | $324 |
| Histosonics, Inc. | 1 | $172 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $136 |
| Dornier Medtech America, Inc | 2 | $133 |
| Astellas Pharma US Inc | 1 | $115 |
| 180 Medical, Inc. | 5 | $108 |
| Coloplast | 3 | $81 |
| Ambu Inc. | 1 | $69 |
| Merck | 2 | $65 |
| Novo Nordisk | 2 | $50 |
| Profound Medical Corp. | 1 | $42 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| Richard Wolf Medical Instruments Corp. | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| ABC Home Medical Supply, Inc. | 1 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| BD | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$118,207
- NEPHROMAX$57,000
- GENERAL - THERAPIES$32,941
- NEPHROSCOPE MIP M$20,500
- Lumenis Pulse 120H$18,312
- (815) Thiola$10,425
- Monarch Platform$9,774
- UROMAX ULTRA$9,200
- CVAC Aspiration System$6,757
- Cook$6,262
- HD-VIEW$6,000
- GENERAL BPH$6,000
- Cook Medical Dilation/Access$5,145
- S~Curve$5,051
- MONARCH$4,000
- Cook Medical Perc Sets$3,150
- LITHO 150$2,605
- LithoVue$471
- PERCUTANEOUS TRACT KIT$266
- Cook Medical Lasers$255
How this compares
$356,256 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 15 | $14,955 |
| Potassium Citrate ErPotassium Citrate | 67 | $7,373 |
| Tamsulosin Hcl | 79 | $1,992 |
| Chlorthalidone | 21 | $393 |
| Allopurinol | 16 | $320 |
| Finasteride | 12 | $180 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $115 | $14,95515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in San Diego
- Elward CrawfordSan Diego$849K
- Emily ColeSan Diego$261K
- Seth BechisSan Diego$260K
- Tung-Chin HsiehSan Diego$240K
- Mark PeSan Diego$226K
- Irwin GoldsteinSan Diego$178K
- Manoj MongaSan Diego$154K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.